These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 24073949)

  • 1. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients -  single center experience].
    Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
    Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
    Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
    Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the Boston University staging system in AL amyloidosis.
    Tomlinson R; Matigian N; Mollee P
    Amyloid; 2019 Sep; 26(3):125-127. PubMed ID: 31145007
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
    Dispenzieri A; Gertz MA; Kyle RA; Lacy MQ; Burritt MF; Therneau TM; Greipp PR; Witzig TE; Lust JA; Rajkumar SV; Fonseca R; Zeldenrust SR; McGregor CG; Jaffe AS
    J Clin Oncol; 2004 Sep; 22(18):3751-7. PubMed ID: 15365071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study.
    Zaroui A; Kharoubi M; Gounot R; Oghina S; Degoutte C; Bezard M; Galat A; Guendouz S; Roulin L; Audard V; Leroy V; Teiger E; Poullot E; Molinier-Frenkel V; Le Bras F; Belhadj K; Bastard JP; Fellahi S; Shourick J; Lemonier F; Damy T
    ESC Heart Fail; 2024 Jun; 11(3):1707-1719. PubMed ID: 38444090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
    Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
    JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.
    Dispenzieri A; Gertz MA; Kumar SK; Lacy MQ; Kyle RA; Saenger AK; Grogan M; Zeldenrust SR; Hayman SR; Buadi F; Greipp PR; Leung N; Russell SR; Dingli D; Lust JA; Rajkumar SV; Jaffe AS
    Heart; 2014 Mar; 100(5):383-8. PubMed ID: 24402772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
    Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
    Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.
    Lilleness B; Ruberg FL; Mussinelli R; Doros G; Sanchorawala V
    Blood; 2019 Jan; 133(3):215-223. PubMed ID: 30333122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
    Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
    Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters.
    Lei C; Zhu X; Hsi DH; Wang J; Zuo L; Ta S; Yang Q; Xu L; Zhao X; Wang Y; Sun S; Liu L
    BMC Cardiovasc Disord; 2021 Jan; 21(1):43. PubMed ID: 33478398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
    Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Colby C; Laumann K; Zeldenrust SR; Leung N; Dingli D; Greipp PR; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Gertz MA
    J Clin Oncol; 2012 Mar; 30(9):989-95. PubMed ID: 22331953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic values of novel biomarkers in patients with AL amyloidosis.
    Kim D; Lee GY; Choi JO; Kim K; Kim SJ; Ju ES; Jeon ES
    Sci Rep; 2019 Aug; 9(1):12200. PubMed ID: 31434944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
    Kristen AV; Maurer MS; Rapezzi C; Mundayat R; Suhr OB; Damy T;
    PLoS One; 2017; 12(4):e0173086. PubMed ID: 28384285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.
    Palladini G; Barassi A; Klersy C; Pacciolla R; Milani P; Sarais G; Perlini S; Albertini R; Russo P; Foli A; Bragotti LZ; Obici L; Moratti R; Melzi d'Eril GV; Merlini G
    Blood; 2010 Nov; 116(18):3426-30. PubMed ID: 20644111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in Japan.
    Fuchida SI; Ide D; Taminishi-Katsuragawa Y; Suga T; Matsui-Maegawa S; Maruyama N; Iwamura Y; Kitamura Y; Okawa Y; Okano A; Hatsuse M; Murakami S; Shimazaki C
    Int J Hematol; 2020 Jun; 111(6):803-811. PubMed ID: 32020505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis.
    Vergaro G; Castiglione V; Aimo A; Prontera C; Masotti S; Musetti V; Nicol M; Cohen Solal A; Logeart D; Georgiopoulos G; Chubuchny V; Giannoni A; Clerico A; Buda G; Patel KN; Razvi Y; Patel R; Wechalekar A; Lachmann H; Hawkins PN; Passino C; Gillmore J; Emdin M; Fontana M
    Eur J Heart Fail; 2023 Mar; 25(3):335-346. PubMed ID: 36597836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of troponin and NT-proBNP to screen for cardiac amyloidosis after carpal tunnel syndrome surgery.
    Noory N; Westin O; Fosbøl E; Maurer MS; Gustafsson F
    Int J Cardiol; 2024 Nov; 415():132469. PubMed ID: 39181411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
    Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
    J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor.
    Kristen AV; Rinn J; Hegenbart U; Lindenmaier D; Merkle C; Röcken C; Hardt S; Giannitsis E; Katus HA
    Clin Res Cardiol; 2015 Mar; 104(3):250-7. PubMed ID: 25331161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.